arrow
M

Milada Zemanová

palacky university olomouc
H指数:24
被引数:5,482

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

度伐利尤单抗(D)作为局限期小细胞肺癌(LS-SCLC)的巩固治疗:ADRIATIC试验中根据既往同步化放疗(cCRT)方案和预防性脑照射(PCI)使用情况的结果

2025-02-010
PRE
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

局限期小细胞肺癌放化疗后的Durvalumab

2024-10-108
PRE
Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients - who's the,good responder?
2021-11-250
PRE
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
2021-03-0149
OAAI
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment - prospective data from the Czech TULUNG registry
2020-10-280
PRE
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
LANCET
IF88.5
2019-11-011.4K
PREAI
Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic
2018-11-190
PRE
Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
2017-12-060
PRE
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis

转移性肾细胞癌患者在靶向治疗中获得完全缓解的结果: 一项基于登记的分析

2016-09-0139
PREAI